These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase. Stafford JA; Veal JM; Feldman PL; Valvano NL; Baer PG; Brackeen MF; Brawley ES; Connolly KM; Domanico PL; Han B J Med Chem; 1995 Dec; 38(26):4972-5. PubMed ID: 8544172 [No Abstract] [Full Text] [Related]
28. The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one. Baures PW; Eggleston DS; Erhard KF; Cieslinski LB; Torphy TJ; Christensen SB J Med Chem; 1993 Oct; 36(22):3274-7. PubMed ID: 8230117 [TBL] [Abstract][Full Text] [Related]
29. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one. Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613 [TBL] [Abstract][Full Text] [Related]
31. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea. Ellis JL; Conanan ND J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355 [TBL] [Abstract][Full Text] [Related]
32. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Nakata A; Ogawa K; Sasaki T; Koyama N; Wada K; Kotera J; Kikkawa H; Omori K; Kaminuma O Clin Exp Immunol; 2002 Jun; 128(3):460-6. PubMed ID: 12067300 [TBL] [Abstract][Full Text] [Related]
33. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1. Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876 [TBL] [Abstract][Full Text] [Related]
34. Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors. Tait A; Luppi A; Hatzelmann A; Fossa P; Mosti L Bioorg Med Chem; 2005 Feb; 13(4):1393-402. PubMed ID: 15670947 [TBL] [Abstract][Full Text] [Related]
35. Structure-activity relationships of alkylxanthine inhibitors of phosphodiesterase IV isoenzyme. Yamamoto K; Sawanishi H; Miyamoto K Biol Pharm Bull; 1998 Apr; 21(4):356-9. PubMed ID: 9586572 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells. Whalen MM; Crews JD Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124 [TBL] [Abstract][Full Text] [Related]
37. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. Kulkarni SS; Patel MR; Talele TT Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198 [TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase. Brackeen MF; Cowan DJ; Stafford JA; Schoenen FJ; Veal JM; Domanico PL; Rose D; Strickland AB; Verghese M; Feldman PL J Med Chem; 1995 Nov; 38(24):4848-54. PubMed ID: 7490734 [TBL] [Abstract][Full Text] [Related]
40. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones. Van der Mey M; Hatzelmann A; Van Klink GP; Van der Laan IJ; Sterk GJ; Thibaut U; Ulrich WR; Timmerman H J Med Chem; 2001 Aug; 44(16):2523-35. PubMed ID: 11472206 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]